What is ABBV's 12-month stock price target?

AbbVie Inc. (ABBV) carries a 12-month consensus base price target of $320.03 (+10.8% from $288.84), with a bull-case target of $377.64 and a bear-case floor of $236.85.

Stock Ratings / Health Care / ABBV / forecast

JNJ (83) MRK (80) NVS (67) AZN (67) ⌘ Pro Terminal →

AbbVie Inc. (ABBV) 12-Month Stock Forecast & Price Target Cone

Q: Is ABBV stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ABBV A- (Buy — BUY) with an RQD Confidence score of 82/100.

$288.84 -2.05% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $288.47

AbbVie Inc. (ABBV) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (70.2% gross margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $521.11B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABBV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABBV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, AbbVie Inc. (NYSE: ABBV) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $288.84 (-2.05% 1D, market cap $521.11B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 20/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ABBV ranks #12 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABBV compare to JNJ and MRK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABBV carries a Roarable A- (82/100 RQD), trailing P/E of 121.6x, gross margin of 70.2%, and ROIC of 29.0%. By comparison, JNJ (Johnson & Johnson) holds a A- grade (83/100 RQD, P/E 24.7x, ROIC 25.5%, cap $657.68B) and MRK (Merck & Company Inc.) posts a B+ grade (80/100 RQD, P/E 19.8x, ROIC 20.7%, cap $368.89B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABBV?

▼

Per ABBV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551152), AbbVie Inc. generated $61.16B in revenue (+8.6% YoY), $4.23B in net income, and $17.82B in free cash flow against $133.96B in total assets and $31.35B in total debt. Key quantitative strengths: Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 122x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $288.46 (-0.13%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 29.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABBV)Realized 20D OHLCV Swing Band: ±4.8%

Deterministic 5-Pillar Attribution (82/100 Composite)

🔍 WHY ABBV SCORES 82/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+20/20 pts (24% of score)

20D Institutional Volume Accumulation (±4.8% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+18/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 29.1% FCF Margin ($17.82B FCF) & 70.2% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution13/20 pts (-7 pt drag)

Cannibal Buyback (-1.52% YoY Shares) & executive Form 4 sales trim 7 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$283.48+0.5% Next Q

Q2 (-2Q)

Grade B+$284.80+0.4% Next Q

Q3 (-1Q)

Grade A-$285.99+1% Next Q

Current

Grade A-$288.84+8.6% Hist 90D α

Trajectory: B+ (74) → A- (82)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ABBV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 82/100 (A-) score, ABBV faces multiple-compression risk if 121.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 122x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 67.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($270.91) or 200D SMA ($238.25) invalidates the momentum regime and cuts Target Base ($320.03) toward Bear Floor ($236.85).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABBV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ABBV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 82%NO 18%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ABBV Position Size: $10,000

Shares at $288.84: 34.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $236.85

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $320.03

$11,080

+$1,080 (+10.8%)

12M Bull Case BreakoutTarget $377.64

$13,074

+$3,074 (+30.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$333	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$355	69%	B
JP MorganUS Large-Cap Research	HOLD	$278	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ABBV Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABBV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +38.76%▲ ASCENDING CHANNEL

2026-11-03O $290.8H $294.9L $288.8C $288.8VOL 6.90M

RES: $300.6SUP: $269.0SMA50: $270.9SMA200: $238.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABBV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABBV Butterfly Map → + Track ABBV →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABBV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABBV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABBV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABBV)

Health Care Rank #12 of 1015 ⚔️ JNJ vs ABBV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABBV vs. JNJ, MRK, NVS, AZN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AbbVie Inc. (ABBV) ranks #12 by composite RQD confidence (82/100, grade A-) and #3 by equity capitalization ($521.11B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with ABBV at 82/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABBV ACTIVE AbbVie Inc.	A-	82/100	121.6x	70.2%	29.0%	-2.05%	$521.11B	Benchmark Subject
JNJ Johnson & Johnson	A-	83/100	24.7x	67.9%	25.5%	-0.97%	$657.68B	/jnj-vs-abbv →
MRK Merck & Company Inc.	B+	80/100	19.8x	74.8%	20.7%	-0.78%	$368.89B	/mrk-vs-abbv →
NVS Novartis AG	C+	67/100	32.8x	—	9.9%	+0.45%	$306.81B	/nvs-vs-abbv →
AZN AstraZeneca PLC	C+	67/100	32.8x	—	9.9%	-0.04%	$289.44B	/azn-vs-abbv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001551152 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AbbVie Inc. (ABBV) reported GAAP revenue of $61.16B (+8.6% vs. FY2024 revenue of $56.33B , and +12.6% cumulative change since FY2023) , GAAP net income of $4.23B, operating cash flow of $19.03B, and free cash flow of $17.82B (-0.1% YoY). On the balance sheet, ABBV closed FY2025 with $133.96B in total assets against $31.35B in total debt (Altman Z-Score: 5.33, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$61.16B	$4.23B	$19.03B	$17.82B	$133.96B	$31.35B
FY2024 (FY)	2024-12-31	$56.33B	$4.28B	$18.81B	$17.83B	$135.16B	$31.63B
FY2023 (FY)	2023-12-31	$54.32B	$4.86B	$22.84B	$20.39B	$282.62B	$66.13B

3. ABBV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABBV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ABBV compare to JNJ and MRK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ABBV?

Where is ABBV trading relative to its 50-day, 200-day, and 52-week technical levels?

ABBV last traded at $288.84 (-2.05% on volume of 8,850,123 shares), positioning the stock +6.62% above its 50-day simple moving average ($270.91) and +21.23% above its 200-day simple moving average ($238.25). Across its 52-week range of $190.75 to $298.74, ABBV sits at the 90.8% percentile with a 14-day RSI of 68.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($274.98 to $302.70).

Direct Sub-Reports: ABBV RQD Cockpit ABBV 12M Forecast ABBV Earnings & Move ABBV Dividends & DRIP ABBV Insiders & 13F ABBV Whale Options ABBV Profit Sankey ABBV News & Why

ROARABLE RATING BRIEF • RQD 82/100 (A-) ✓ SEC XBRL & RQD VERIFIED

ABBV — AbbVie Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AbbVie Inc. (ABBV) earns a live Roarable RQD composite score of 82/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $288.84 (-2.05% 1D, market capitalization $521.11B).

Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 29.0%, gross margin of 70.2%, operating margin of 24.6%, and free cash flow yield of 3.47%.
Whale 13F & Options Flow (20/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (16/20): Incorporates a 1.15x equity beta, Altman Z-Score of 5.33, Piotroski F-Score of 7/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

AbbVie Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AbbVie Inc. (ABBV) reported $61.16B in annual revenue (up from $56.33B in FY2024, +8.6% YoY) and $4.23B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($54.32B revenue, $4.86B net income) through FY2025, ABBV scaled operating cash flow to $19.03B and free cash flow to $17.82B, backed by $133.96B in total assets against $31.35B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (A- • RQD 82/100): Strong cash generator (70.2% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 20/20, sustained execution supports upside toward the upper end of the $190.75 – $298.74 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 122x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 121.6x trailing P/E and 33.3x EV/EBITDA against 24.6% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The investor implication is that the source provides no mapped second-order exposures, so any ripple analysis would fall outside the supplied evidence.

Key Question #1: Can ABBV sustain or expand its 24.6% operating margin and 29.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $61.16B and free cash flow of $17.82B, how will capital allocation balance growth reinvestment against $31.35B in total debt?
Key Question #3: How sensitive is ABBV's 113.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

ABBV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AbbVie Inc. (ABBV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABBV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Why AbbVie (ABBV) Outpaced the Stock Market Today

Yahoo Finance report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis

TradingKey report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE 24/7 Wall St. • 1d ago

Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape

24/7 Wall St. report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Should You Buy AbbVie Stock Before Oct. 30?

Yahoo Finance report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline Wins

Yahoo Finance report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?

Yahoo Finance report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands

Yahoo Finance report covering AbbVie Inc. (ABBV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABBV Bull vs. Bear Conversation Board — What's Your Call at $288.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABBV 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $339.12 (+15.0%)

📌 Pinned Debate

ROIC of 29% and a 19/20 whale-flow pillar signal strong capital efficiency and institutional accumulation.

ROIC of 29% and a 19/20 whale-flow pillar signal strong capital efficiency and institutional accumulation.. When you look under the hood at ABBV, Fundamental Cash Engine is 18/20 with 70.2% gross margins and 29.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (20/20) has been quietly accumulating below $298.74. My 12M target is $339.12.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ABBV's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $241.81 (-18.0%)

Spot @ $294.89

A P/E (TTM) of 121.6 and an FCF yield of 3.47% leave little valuation cushion against the 1.15 beta.

Here is the bear case nobody on the bull side wants to address on ABBV: A P/E (TTM) of 121.6 and an FCF yield of 3.47% leave little valuation cushion against the 1.15 beta.. At 121.6x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.